The trajectory of companies tied to Viagra's history presents a complex investment scenario . While the initial success generated substantial gains, generic copies have significantly eroded revenue. Investing in connected pharmaceutical companies now requires a discerning assessment of proprietary safeguards, evolving medical trends , and the prosp